Tel: LO CALL: 1850 918 133

Ailesbury Clinic Blog

NICE recommends ixekizumab for psoriasis

The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.

The guidance recommended ixekizumab as an option for treating plaque psoriasis in adults, but only if they had severe disease (a total psoriasis area and severity index (PASI) score of 10 or more), which had not responded to standard systemic therapies such as ciclosporin or methotrexate or for patients in whom these were contraindicated or not tolerated.1

Ixekizumab is given by subcutaneous injection at a dose of 80 mg every two weeks for 12 weeks and then every four weeks. The list price is £1125 (€1300; $1370) for the 80 mg dose, but NICE has recommended that it be used only at the discounted cost agreed in a patient access scheme with the manufacturer.

The NICE draft appraisal recommended that ixekizumab be stopped after 12 weeks if a patient’s psoriasis had not responded adequately. Adequate response was defined as a 75% reduction in PASI score from when treatment started or a 50% reduction in PASI score together with a five point reduction in the dermatology life quality index.

After reviewing the available evidence the NICE appraisal committee concluded that ixekizumab was more clinically effective than placebo or etanercept (a tumour necrosis factor inhibitor) and had similar side effects to other biological treatments. The committee found that the incremental cost effectiveness ratio was within the range considered to be a cost effective use of NHS resources.

The draft guidance is out for consultation, and NHS organisations can make decisions on its use locally until it is finalised. If NICE confirms the draft recommendations the NHS must make sure it is available within three months of the final guidance being published.

 

1. NICE. Final appraisal determination. Ixekizumab for treating moderate to severe plaque psoriasis. March 2017. https://www.nice.org.uk/guidance/GID-TA10063/documents/final-appraisal-determination-document.

dublin map

Ailesbury Dublin
David Lloyd Riverview,

1st Floor,
Beech Hill Road,
Donnybrook  Dublin 4.

Tel:   (01)269 2255 / (01)269 2133
Fax: (01)269 2250
Email:reception@ailesburyclinic.ie

 

 

 

cork map

Ailesbury Cork

Holbar House
East Village
Douglas, Cork.

Tel: (01) 269 2255

Cork (021) 4835006

Email:reception@ailesburyclinic.ie    

 

 

 

 

 

 

 

 

 

 

patrick treacy

AMEC AWARDS 2014 & 2016

Ailesbury Clinics are the only clinic in the world to have won two AMEC Awards and ' Best Medical Research in Ireland 2017'. Specialists in Dermatology and Aesthetic Medicine. We perform minor surgery + skin cancer screen. VHI, Aviva, Laya and Irish Health accepted. Hstopathology performed at St. Vincent's University Hospital, Dublin. Consultation €120  READ MORE Please read all of our Ailesbury Clinic BLOGS

 

  Image result for vhi avivaImage result for blog